The Global Anti-Hypertensives Market is Set to Show Flat Growth in the Near Future

Tuesday 10 April 2012, Amsterdam

The Global Anti-Hypertensives Market is Set to Show Flat Growth in the Near Future
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of hypertension and pulmonary arterial hypertension. It also provides the share of generics in global anti-hypertensives and in each indication market. The report examines the global anti-hypertensives usage patterns. It includes the geographical distribution of hypertension and PAH disease markets across the US, the top five countries of Europe and in Japan. The report also includes insights into the anti-hypertensives Research and Development (R&D) product pipeline and explores the competitive landscape, including major players in the anti-hypertensives market. Finally, the report includes analysis on Mergers and Acquisitions (M&A) and licensing agreements that took place in the anti-hypertensives market. GBI Research’s analysis shows that the overall global anti-hypertensives market for two indications, hypertension and pulmonary arterial hypertension, was valued at $29.9 billion in 2010. It grew from $19.1 billion in 2002 at a CAGR of 5.8%. The market is expected to witness a fluctuation due to patent expiries followed by generic erosion and the possible launch of novel molecules. The market is expected to witness comparatively slow growth with a CAGR of 1.2% between 2010 and 2017, to reach $32.6 billion in 2017. A steady increase in the hypertension and PAH prevalence population and the use of fixed dose combination drugs will drive the growth of the anti-hypertensives market in the future. The market for hypertension market is expected to slow down due to patent expiries of major blockbuster drugs. Recent and upcoming patent expiries of drugs are the only barrier to the global anti-hypertensives market. However, the expected launch of novel molecules with disease modifying characteristics and better safety and efficacy will drive the market in the forecast period.


The Global Anti-Hypertensives Market is Set to Show Flat Growth in the Near Future

See figure: Anti-Hypertensives Market, Global, Revenue Forecasts ($bn), 2002, 2010 and 2017

The global anti-hypertensives market was estimated to be worth $29.9 billion in 2010, representing a Compound Annual Growth Rate (CAGR) of 5.8% between 2002 and 2010. The market is forecast to reach $33 billion by 2017 at a CAGR of 1.2%. The primary reason for the slow down in the market growth is the patent expiries of major blockbusters in the forecast period. Drugs that are set to lose patent include Novartis’ Diovan (2012), Sanofi’s Avapro (2012), Novartis’s Exforge (2012), Takeda/AstraZeneca’s Blopress/Atacand (2012), Pfizer’s Revatio (2012), Boehringer’s Micardis (2014), United Therapeutics Remodulin (2014), Actelion’s Tracleer (2015) and Daiichi Sankyo’s Benicar (2016). These drugs together accounted for more than $20.6 billion in revenues in 2010. However, the market is expected to rise slightly after 2015 due to increased usage of fixed dosecombinations and the increase in prescription population on generics. The new fixed dose combinations which entered the antihypertensives market recently are Exforge HCT, Tektuna HCT, Tekamlo, Valturna, Tribenzor, Twynsta, Edarbi and Amturnide. The current anti-hypertensives pipeline offers some promising novel products indicated for the treatment of hypertension and PAH such as SPP635, Actos, LCZ696, QT1571, ACT-293987, PS-433540, Macitentan and Riociguat. However, the revenues that will be generated from these products are not expected to completely make up for the revenue losses due to patent expiries.


Top Six Companies Contribute About 76% of the Market

The current global anti-hypertensives market is dominated by the top six players with 76% of the market share. Novartis is the current market leader with 28% of the market share due to its blockbuster drug Diovan which made sales of six billion US dollars in 2010. Novartis’ other major products in the anti-hypertensives market are Exforge, Tekturna/Rasilez, Lotrel and Lescol. Daiichi Sankyo is the second largest player with 14% of the market share. Benicar is the top selling drug in Daiichi Sankyo’s anti-hypertensives drug portfolio. AstraZeneca and Sanofi occupy third position with 10% of each due to their top selling drugs Atacand and Avapro respectively. Pfizer’s Norvasc and Merck’s Cozaar lost their patents in 2007 and 2010 respectively which landed up Pfizer and Merck with 7% of market share each. However, Pfizer’s Revatio is one of the top selling drug in the PAH market. Boehringer Ingelheim also has a significant share in the market with its drug Micardis. Actelion is the market leader in PAH market with its blockbuster drugs Tracleer and Ventavis and occupies 6% of the market share.

However, the market shares of the total players are expected to witness changes in the future due to upcoming patent expiries. Novartis’ Diovan, Exforge and Tekturna/Rasilez are set to expire in 2012. Daiichi Sankyo is expected to lead the market with its Benicar whose patent is valid until 2014.


Novartis to Lead the Anti-Hypertensives Market

The anti-hypertensives drug category was the largest selling subcategory of the cardiovascular market in 2010. Novartis is the market leader in the anti-hypertensives market, with a large number of marketed products. Key products of Novartis include Diovan, Diovan HCT, Exforge, Tekturna/Rasilez, Lotrel and Lescol. Boehringer Ingelheim’s Micardis, Daiichi Sankyo’s Benicar, Takeda’s Blopress and AstraZeneca’s Atacand are other top selling drugs. Pfizer’s Norvasc was the market leader until 2007. Norvasc went off-patent in 2007, giving a major share of the market to Novartis’ Diovan and Merck’s Cozaar. The first ARB to lose patent was Cozaar in April 2010. Novartis’ Diovan is set to lose patent in 2012. Novartis launched its other fixed dose combination drugs in 2010 such as Exforge HCT, Tektuna HCT, Tekamlo, Valturna and Amturnide. These drugs together with the earlier drugs expect to keep Novartis the anti-hypertensives market leader. Sanofi’s Avapro is also one of the leading drugs in the anti-hypertensives market, registering high sales over the years. It is also expected to go off-patent in 2012. Actelion’s Tracleer, the most prescribed PAH therapy in the world, is set to expire in 2015. Thus Novartis will lead the antihypertensives market with a large number of blockbuster drugs and fixed dose combination drugs.
Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion

Anti-Hypertensives Market to 2017 - Patent Expiries of Blockbusters such as Diovan, Micardis, Avapro and Atacand to Accelerate Erosion

Publish date : March 2012
Report code : ASDR-9495
Pages : 119

ASDReports.com contact: S. Koomen

ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216

 back to News